Breathe Well Live Well
|
Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD
Reuters (press release) Nycomed / Nycomed and Orion Corporation to collaborate on Easyhaler® for asthma and COPD . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Nycomed announced today that it has … |
View full post on asthma – Google News
|
Government plan targets COPD sufferers
Management in Practice The government outcomes strategy for chronic obstructive pulmonary disease (COPD) and asthma aims to transform the lives of people living with lung conditions including emphysema and chronic bronchitis. The new plans will bring together the work of … Government announces COPD and asthma strategy Government outlines new strategy to combat respiratory illness |
View full post on asthma – Google News
|
Government announces COPD and asthma strategy
Nursing Times The government outcomes strategy for Chronic Obstructive Pulmonary Disease (COPD) and asthma is intended to improve the lives of patients with breathing difficulties by coordinating the efforts of the NHS, social care and voluntary organisations. … |
View full post on asthma – Google News
|
DoH publishes COPD and asthma strategy
GP online Publication of the DoH's long-awaited COPD and asthma outcomes strategy has been welcomed by lung charities. The outcomes strategy for COPD and asthma in England calls for practices to stratify asthma patients by their risk … National strategy announced for respiratory disease |
View full post on asthma – Google News
|
Breathe easy Early diagnosis, treatment key to COPD management
The Mercury COPD can also be caused by air pollution (including secondary smoke and exposure to occupational dust, gas, chemicals and toxic fumes), asthma and respiratory infections. People who work or have worked in industrial environments are also at risk. … |
View full post on asthma – Google News
 HealthNews |
U.S. Rates of COPD Stabilize While Women Show Higher Occurrence
HealthNews Both COPD and asthma are forms of chronic lower respiratory disease (CLRD), the third leading cause of death in the United States in 2008. During the period from 2007 through 2009, 11.8 million adults were diagnosed with COPD. While asthma has been … |
View full post on asthma – Google News
|
Research and Markets: the Asthma, COPD & Allergic Rhinitis Market Outlook to …
Business Wire (press release) The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical … |
View full post on asthma – Google News
|
Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
Centre Daily Times The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical … |
View full post on asthma – Google News
|
Reportlinker Adds The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
SYS-CON Media (press release) The global respiratory market was valued at $44.0bn in sales in 2010 with asthma/COPD drugs being the key revenue drivers of the therapeutic segment. Of respiratory indications, asthma represents the main area of R&D interest for pharmaceutical … |
View full post on asthma – Google News
|
GSK sees positive results on asthma, COPD drug expected to succeed Advair
MedCity News The results boost the compound's prospects as a successor to GSK's blockbuster asthma and COPD drug Advair, whose patents have expired. London-based GSK, which maintains its US headquarters in Research Triangle Park, North Carolina, and drug partner … GSK gets good news on asthma drug Glaxo Drug Gets Positive Trial Results Theravance, Glaxo Lung Drug Passes Two Pivotal Trials; Two More to Go |
View full post on asthma – Google News